Monument Tx is an independent UK based biotechnology company formed as a spin-out from Cambridge Cognition in 2021. Monument Tx develops products to treat serious diseases of the central nervous system. Our precision medicine approach utilises proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds. Using biomarkers to more accurately identify patients with a disease sub-type most likely to respond to a particular treatment is already successfully used in the treatment of cancer. Now Monument Tx brings digital biomarkers to neuroscience drug development to provide a precision medicine approach in clinical areas of high unmet need. Contact us to learn more about our company and solutions.
Location: United Kingdom, England, Macclesfield
Employees: 1-10
Total raised: $2.38M
Founded date: 2019
Investors 4
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 13.05.2025 | Angel CoFu... | acfinvesto... |
| 15.09.2024 | Syndicate ... | syndicater... |
| 01.07.2021 | Cambridge ... | cambridgea... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.02.2025 | - | $1.07M | - |
| 15.10.2024 | - | $1.31M | - |
Mentions in press and media 14
| Date | Title | Description |
| 10.03.2026 | Monument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for Psychosis | Monument Therapeutics Logo MANCHESTER, UNITED KINGDOM, March 10, 2026 /EINPresswire.com/ -- Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial... |
| 20.08.2025 | Monument Therapeutics to trial schizophrenia therapy in partnership with FNIH | - |
| 23.06.2025 | Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment | - |
| 23.06.2025 | Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment in Schizophrenia Treatment | MANCHESTER, UNITED KINGDOM, June 23, 2025 /EINPresswire.com/ -- Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting... |
| 17.04.2025 | Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board | - |
| 01.03.2025 | Monument Therapeutics: Pioneering a New Path in Schizophrenia Treatment | In the realm of mental health, schizophrenia stands as a formidable adversary. It affects around 20 million people globally, casting a long shadow over their lives. Among its many symptoms, cognitive impairment associated with schizophrenia... |
| 25.02.2025 | Monument Therapeutics secures £850K to advance schizophrenia treatment with MT1988 | Schizophrenia affects approximately 20 million people worldwide. One of the core symptoms is Cognitive impairment associated with schizophrenia (CIAS), which impacts memory, attention, and executive function, significantly reducing patients... |
| 25.02.2025 | Monument Therapeutics Raises £850K in Further Funding | Monument Therapeutics, a Manchester, UK-based neuroscience company applying digital biomarkers to psychiatric drug development, raised £850K in further funding. The round was led by ACF Investors, with participation from Wren Capital, o2h V... |
| 15.10.2024 | Monument Therapeutics Receives £1M Investment | Monument Therapeutics, a Manchester, UK-based precision neuroscience company, received a £1M equity investment from the Forster Foundation. The company intends to use the funds to support the clinical development of MT1988, a novel treatmen... |
| 04.01.2024 | Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia | - |
Show more